JAZF1 heterozygous knockout mice show altered adipose development and metabolism
Cell & Bioscience volume 11, Article number: 161 (2021)
Juxtaposed with another zinc finger protein 1 (JAZF1) is associated with metabolic disorders, including type 2 diabetes mellitus (T2DM). Several studies showed that JAZF1 and body fat mass are closely related. We attempted to elucidate the JAZF1 functions on adipose development and related metabolism using in vitro and in vivo models.
The JAZF1 expression was precisely regulated during adipocyte differentiation of 3T3-L1 preadipocyte and mouse embryonic fibroblasts (MEFs). Homozygous JAZF1 deletion (JAZF1-KO) resulted in impaired adipocyte differentiation in MEF. The JAZF1 role in adipocyte differentiation was demonstrated by the regulation of PPARγ—a key regulator of adipocyte differentiation. Heterozygous JAZF1 deletion (JAZF1-Het) mice fed a normal diet (ND) or a high-fat diet (HFD) had less adipose tissue mass and impaired glucose homeostasis than the control (JAZF1-Cont) mice. However, other metabolic organs, such as brown adipose tissue and liver, were negligible effect on JAZF1 deficiency.
Our findings emphasized the JAZF1 role in adipocyte differentiation and related metabolism through the heterozygous knockout mice. This study provides new insights into the JAZF1 function in adipose development and metabolism, informing strategies for treating obesity and related metabolic disorders.
A recent genome-wide association study indicated that new variants in gene loci modestly affect the risk of type 2 diabetes mellitus (T2DM) and related metabolic disorders. Here, variants from six genes, namely, JAZF1, TSPAN8, THADA, ADAMTS9, CDC123/CAMK1D, and NOTCH2, are genes closely associated with T2DM and metabolic disorders .
Several reports show that genetic variants within JAZF1 cause metabolic disorders that downregulate JAZF1 expression, and these genetic variations are also correlated with decreased body mass index (BMI) and waist circumference [1, 2]. Studies assessing the JAZF1 role in glucose and lipid metabolism and showed that JAZF1 overexpression reduced adipocyte differentiation in 3T3-L1 preadipocyte in vitro and mentioned that JAZF1 is a negative regulator in adipocyte differentiation [11,12,13,14]. Nevertheless, these data indicated that JAZF1 expression was paradoxically upregulated with adipocyte differentiation markers. Moreover, JAZF1, which promotes visfatin expression in mature adipocytes, was mediated by the peroxisome proliferator-activated receptor α (PPARα) and PPARβ/δ .
Interestingly, in our preliminary analyses in human adipose tissue from obese subjects, we found that increased JAZF1 expression in several microarray-based mRNA expression profiles (GSE2508, GSE9624, and GSE16415, Additional file 1: Figure S1a–c) [4,5,6]. A recent study demonstrated that JAZF1 represses nuclear receptor subfamily 2, group C, member 2 (NR2C2)-mediated transcription in vitro through their interaction . Moreover, the NR2C2-knockout mice showed decreased adipose development, obesity-related inflammation, hepatic steatosis, and insulin resistance . Thus, JAZF1 might influence metabolic regulation, adipose development, adipocyte differentiation, obesity, and insulin resistance through indirectly NR2C2-mediated transcriptional regulation.
We used the 3T3-L1 preadipocyte—a widely used model for adipogenic differentiation and mouse embryonic fibroblasts (MEFs) from the homozygous JAZF1 deletion (JAZF1-KO) mice—to explore the JAZF1 function in adipocyte differentiation related to metabolic disorders. Besides, the JAZF1 role in adipocyte differentiation, adipose tissue mass, and metabolic regulation was examined with heterozygous JAZF1 deletion (JAZF1-Het) mice fed a normal diet (ND) or a high-fat diet (HFD). The in vitro and in vivo models of JAZF1 deficiency allowed us to investigate the relationship between JAZF1 and adipose development and metabolism, helping us better understand the specific JAZF1 functions.
JAZF1 expression during 3T3-L1 preadipocyte differentiation
3T3-L1 preadipocytes have been widely used as an in vitro model for adipocyte biology investigation, including adipocyte differentiation (i.e., adipogenesis) and lipid metabolism [12,13,14]. By using the 3T3-L1 model, we evaluated the JAZF1 mRNA expression during the preadipocyte differentiation, which can be divided into two stages: the early (days 0–2) and terminal stage (days 2–8) .
The JAZF1 mRNA expression was elevated mostly during the terminal adipocyte differentiation stage (Fig. 1a). We additionally checked the adipogenic markers to confirm the relation between JAZF1 and terminal differentiation. PPARγ2 and CCAAT-enhancer-binding protein α (C/EBPα) are required for adipocyte differentiation in the terminal stage . The increased PPARγ2 and C/EBPα mRNA expressions are accompanied by a parallel increase in the JAZF1 mRNA expression (Fig. 1a–c). On the other hand, C/EBPβ, which rapidly induced cell proliferation during the early stage of adipocyte differentiation , was inversely correlated with the JAZF1 mRNA expression (Fig. 1a, d). Protein expression pattern of JAZF1 and adipogenic markers (PPARγ2, C/EBPβ) were consistent to mRNA expression levels during adipocyte differentiation (Fig. 1e). A more significantly relative JAZF1 expression is found in mature adipocytes than stromal vascular fractions (SVFs), containing preadipocytes (immature adipocytes, Fig. 1f). These observations suggest that JAZF1 may play regulatory role during adipocyte differentiation.
JAZF1 deficiency impairs adipocyte differentiation in vitro
We generated heterozygous JAZF1 deletion mice and induced adipocyte differentiation in the MEFs isolated from JAZF1-KO, JAZF1-Het, and JAZF-Cont mice embryos in vitro (Fig. 2a, b) to further investigate the JAZF1 role in adipose development and differentiation. Oil red O staining showed that JAZF1-KO MEFs treated with an adipogenic hormone cocktail failed to undergo adipocyte differentiation compared with JAZF1-Cont MEFs (Fig. 2b). JAZF1-Cont MEFs showed the highest adipocyte differentiation level, whereas the adipocyte differentiation level from JAZF1-Het MEFs was intermediate compared to those of both the JAZF1-KO and JAZF1-Cont MEFs (Fig. 2b). Consistently, the JAZF1-KO MEFs showed a profoundly reduced adipogenic marker expression during adipocyte differentiation (12 days), such as PPARγ2, C/EBPα, and fatty acid-binding protein 4 (FABP4), with severe adipocyte differentiation defect (Fig. 2c).
Next, we investigated the time-course mRNA expression of key adipogenic markers in JAZF1-KO and JAZF1-Cont MEFs. As expected, JAZF1 mRNA expression in JAZF1-Cont MEFs increased significantly during the terminal adipocyte differentiation (24 h to 8 days) (Fig. 2d). This result was consistent with the findings in 3T3-L1 preadipocyte differentiation. We investigated the master regulator of adipocyte differentiation, PPARγ and related genes including C/EBPα and FABP4. Unlike the JAZF1-Cont MEF, these genes were not transcriptionally active throughout adipocyte differentiation in JAZF1-KO MEFs (Fig. 2e–g). On the other hand, C/EBPβ, which encodes upstream regulator of PPARγ, was unaltered according to genotypes (Fig. 2h). Both the JAZF1 and adipogenic protein expressions also showed similar patterns, as shown in the mRNA expression level during adipocyte differentiation (Fig. 2i). Overall, JAZF1 deficiency dramatically decreased PPARγ and PPARγ-associated gene expressions.
JAZF1-Het mice showed a lower adipose tissue mass
We generated mice with a targeted mutation at the endogenous JAZF1 locus, using the Cre-loxP system to determine the JAFZ1 involvement more deeply during adipose development and differentiation (Additional file 1: Figure S2a, b). However, the JAZF1 homozygous deletion led to embryonic lethality at E15.5–18.5 days (Additional file 1: Figure S2c). Although a few JAZF1-KO pups survived at birth, they showed severe growth retardation and died within 3 weeks (Additional file 1: Figure S2d). Therefore, we examined adipose development using JAZF1-Het mice.
First, the qRT-PCR results showed that the JAZF1 mRNA expression reduced significantly in eWAT (~ 74%), scWAT (~ 52%), liver (~ 31%), and pancreas (~ 26%) of JAZF1-Het compared with JAZF1-Cont mice (Fig. 3a). The JAZF-Het and the JAZF1-Cont mice were fed with normal diet (ND) for 8 weeks starting at 8-week-old. After 8 weeks of ND feeding, the JAZF-Het mice showed a lower eWAT mass than the JAZF1-Cont mice (Fig. 3b). In the body composition analysis, both subcutaneous and visceral adipose tissue (SAT and VAT, respectively) mass were significantly lower in JAZF1-Het than JAZF1-Cont mice (Fig. 3c, d).
Next, we measured eWAT and scWAT adipocyte diameters and distribution in both the JAZF1-Het and JAZF1-Cont mice (Fig. 3e). The smaller distribution of adipocyte diameters was observed in eWAT and scWAT from the JAZF-Het mice (Fig. 3f, g). However, the nuclei density and genomic DNA contents per adipose tissue (eWAT and scWAT) depots were similar between the genotypes (data not shown).
We performed a qRT-PCR to analyze the molecular changes of adipose tissues [eWAT, scWAT, and brown adipose tissue (BAT)] in the JAZF1-Het mice. We found that the expressions of adipogenic markers were significantly lower in the eWAT and scWAT compared to WT mice (Fig. 4a, b). Nonetheless, as seen in Fig. 3a, JAZF1 did not change significantly in BAT and neither did the mRNA expression of BAT makers (PRDM16, UCP1, and FABP1; Fig. 4c). Besides, lipogenesis-related gene expressions in the liver decreased in JAZF1-Het compared to JAZF1-Cont mice, although histological analysis showed no difference between the two groups (Additional file 1: Figure S3a, b).
We also found JAZF1-Het mice had lower triglyceride (TG) levels and higher nonesterified fatty acids (NEFA) levels in serum (Additional file 1: Figure S4a, b). Serum high-density lipoprotein (HDL) levels decreased in the JAZF1-Het mice, but no difference was observed in serum low-density lipoprotein (LDL) and cholesterol level, independently of the genotype considered (Additional file 1: Figure S4c–e). Together, these results suggest that JAZF1 heterozygous deletion reduced adipose development and affected the lipid profiles in blood circulation.
JAZF1-Het mice showed impaired glucose homeostasis but normal energy metabolism
Interestingly, the change in adipogenic markers was more significant in the eWAT compared to scWAT (Fig. 4a, b). As a visceral adipose tissue, eWAT accumulation is associated with metabolic risks, including insulin resistance. We performed glucose tolerance test (GTT) and insulin tolerance test (ITT) analysis on JAZF1-Het and JAZF1-Cont mice to determine whether a JAZF1 heterozygous deletion could change the systemic glucose homeostasis and insulin sensitivity. Male and female JAZF1-Het mice fed with ND for 8 weeks showed higher blood glucose levels than the JAZF1-Cont mice during the GTT (Fig. 4d, e). The ITT results revealed that the blood glucose levels in male JAZF1-Het mice were higher at 90 and 120 min, and female JAZF1-Het mice were higher at 120 min, following the insulin injection (Fig. 4f, g). Consistently, the area under the curve (AUC) for the glucose levels determined by GTT increased in the male and female JAZF1-Het mice compared with the JAZF1-Cont mice (Fig. 4h). Regarding the AUC glucose level determined from ITT, the male JAZF1-Het mice showed a significant increase compared with male JAZF1-Cont mice. However, female JAZF1-Het mice showed an increased trend in the AUC of the glucose level (p = 0.06) compared with the female JAZF1-Cont mice. According to the genotypes, the serum insulin level in male JAZF1-Het mice was significantly lower than JAZF1-Cont mice, but no difference was observed in female mice (Fig. 4i). The qRT-PCR analysis showed that the mRNA expressions of insulin sensitivity markers (GLUT4, leptin, and adiponectin) were lower in both the eWAT and scWAT in the JAZF1-Het mice. However, both the gluconeogenesis and glucose homeostasis-related gene expressions in their liver did not change with JAZF1 heterozygous deletion (Additional file 1: Figure S5). We investigated insulin signaling in both the JAZF1-Het and JAZF1-Cont mice to determine organ-specific insulin action by JAZF1. We challenged the JAZF1-Het and JAZF1-Cont mice with insulin for 15 min and isolated their eWAT and liver. Western blot analysis showed that insulin-stimulated Protein kinase B (AKT) phosphorylation was significantly lower in the eWAT and liver tissues of the JAZF1-Het mice than that of the JAZF1-Cont mice (Fig. 4j).
Next, we examined energy metabolism in both the JAZF1-Het and JAZF1-Cont mice by checking the amount of oxygen that their body uptakes and utilizes. Through the VO2 and VCO2, we measured the form of oxygen inhaled and exhaled by the mice (Fig. 5a, b). Moreover, we calculated both the energy consumption and respiratory exchange ratio (RER) ratio, using the indirect calorimetry system. The results show no significant difference in energy expenditure according to genoyptes (Fig. 5a–d). Therefore, the JAZF1 heterozygous deletion caused insulin resistance but did not affect energy metabolism.
JAZF1-Het mice fed with a high-fat diet showed less adipose development and affected glucose homeostasis
We fed 8-week-old JAZF1-Het and JAZF1-Cont mice with a high-fat diet (HFD) for 8 weeks (JAZF1-Het-HFD vs. JAZF1-Cont-HFD) to investigate the effect of heterozygous deletion of JAZF1 on adipose development in vivo. JAZF1-Het-HFD mice showed significantly lower weight gain than JAZF1-Cont-HFD mice (Fig. 6a). The JAZF1-Het-HFD mice also exhibited a considerably lower eWAT mass (Fig. 6b, c), and histological analysis of their adipocytes showed that both eWAT and scWAT were smaller (Fig. 6e). We calculated the distribution and mean adipocyte diameters in eWAT and scWAT. These measurements showed a significantly smaller adipocyte distribution and diameter in the JAZF-Het-HFD than in the JAZF1-Cont-HFD mice (Fig. 6f). However, the liver mass (Fig. 6d), nuclei density, and genomic DNA contents per adipose tissue depots (eWAT and scWAT) were similar between the two groups (data not shown). The lipid accumulation in the liver was lower in the JAZF1-Het-HFD than JAZF1-Cont-HFD mice (Additional file 1: Figure S6a).
Next, we performed qRT-PCR analysis to determine the molecular change of adipose tissues in JAZF1-Het-HFD. The expressions of PPARγ2 and genes encoding other adipogenic markers were significantly lower in the eWAT of JAZF1-Het-HFD mice (Fig. 6g). Although both the PPARγ2 and C/EBPα mRNA expressions did not change in the scWAT of JAZF1-Het-HFD mice, the FABP4 mRNA expression decreased significantly (Fig. 6h). However, unlike eWAT and scWAT, JAZF1-Het-HFD mice showed no change in BAT markers compared with JAZF1-Cont-HFD (Fig. 6i), as in the previous results (Fig. 4c). Moreover, lipogenesis-related gene expressions in the liver decreased significantly in JAZF1-Het-HFD compared to JAZF1-Cont-HFD mice (Additional file 1: Figure S6b). In the serum analysis, both the TG and NEFA levels remained unchanged, corroding to genotypes (Additional file 1: Figure S7a, b). Serum HDL land cholesterol levels decreased in the JAZF1-Het-HFD mice, but the LDL level remained unchanged (Additional file 1: Figure S7c–e).
We also determined systemic glucose homeostasis in JAZF1-Het mice after HFD feeding for 8 weeks. The GTT results show that blood glucose levels were significantly higher in both male (at 15 and 30 min) and female (at 15 and 90 min) JAZF1-Het-HFD compared to JAZF1-Cont-HFD mice (Fig. 7a, b). However, the blood glucose level from the ITT remained unchanged according to genotypes (Fig. 7c, d). The AUC blood glucose and serum insulin levels also remained unchanged in male and female JAZF1-Het-HFD compared to JAZF1-Cont-HFD mice (Fig. 7e, f). The mRNA expressions of insulin sensitivity markers tended to decrease in eWAT and scWAT of the JAZF1-Het-HFD mice. However, gluconeogenesis and glucose homeostasis-related genes in the liver remained unchanged in the JAZF1-Het-HFD mice (Additional file 1: Figure S8).
JAZF1-Het mice either fed with ND or HFD showed increased immune cell infiltration
Immune cell infiltration in metabolic tissues is a causative factor in insulin resistance and metabolic disorders . Recent studies indicate that JAZF1-overexpressing mice showed reduced chronic inflammation by regulating macrophage population and inflammatory cytokines in vivo and in vitro [13, 14]. Therefore, we determined whether heterozygous JAZF1 deletion affects the macrophage infiltrations. We either fed both the JAZF1-Het and JAZF1-Cont mice with an ND or HFD for 8 weeks. We stained the eWAT and liver tissues with CD68 antibodies. The immunohistochemical analyses showed that the number of CD68-positive macrophages and monocytes increased significantly in eWAT in the ND-fed JAZF1-Het compared to the ND-fed JAZF1-Cont mice. However, compared to the JAZF1-Cont mice, the JAZF1-Het mice fed with HFD showed a tendency to increase the number of CD68-positive cells in the eWAT tissue (Fig. 8a, p < 0.06). The CD68 positive cells in the liver did not differ between the JAZF1-Het and JAZF1-Cont mice fed with ND, but they increased in the JAZF1-Het compared to the JAZF1-Cont mice, when both groups were fed with an HFD (Fig. 8b).
Here, we generated heterozygous JAZF1-deficient mice and identified the JAZF1 role in adipose development and metabolism. The most critical feature caused by the JAZF1 deficiency was reducing adipose development, which led to insulin resistance. We demonstrated that JAZF1 deletion (homozygous JAZF1-deficient) inhibited adipocyte differentiation in MEFs and 3T3-L1 in vitro experimental models. Furthermore, we demonstrated that JAZF1 partially regulates adipocyte differentiation through PPARγ and JAZF1 interactions, implying that JAZF1 is extensively involved in adipose development and insulin sensitivity.
Recently, attempts have been made to find the pathological JAZF1 regulation mechanism in humans. Several single nucleotide polymorphism risk alleles within the JAZF1 gene, which led to a reduced JAZF1 expression, were associated with decreased BMI, waist circumference, and impaired glucose homeostasis [1, 2, 15,16,17,18]. The observations in our JAZF1-deficient mice are consistent with the results published in these previous reports, which were primarily performed in the JAZF1 overexpression models during adipose development [3, 13, 19,20,21]. Here, we used whole-body CMV-cre to delete JAZF1 in mice and demonstrated that JAZF1 deficiency inhibits adipose development in adipose tissues.
Previous in vitro and in vivo studies indicated that JAZF1 works as a negative regulator in adipose development and differentiation [3, 19,20,21]. Nonetheless, the JAZF1 expression, strictly regulated during adipocyte differentiation, could explain the paradoxical finding we obtained in our research. When the adipocyte is induced to differentiate, growth-arrested preadipocytes reenter the cell cycle with mitotic clonal expansion during the early differentiation stage, followed by the expression of genes that maturate the adipocytes during the terminal differentiation stage. However, in the early differentiation stages, such growth-arrested preadipocytes must exit the cell to undergo terminal differentiation . The JAZF1 expression levels remained low at early differentiation in the 3T3-L1 and MEFs in our in vitro experimental models and robustly increased during the terminal differentiation.
We introduce JAZF1 as a positive regulator of adipocyte development and differentiation and we think the role of JAZF1, privously known as a negative regulator in adipocyte development and differentiation, can be explained from different perspectives. JAZF1 was originally identified as an oncogene that promotes cell cycle progression and induces cell proliferation in tumors [23, 24]. Thus, persistent JAZF1 upregulation may interrupt the exit from the cell cycle during the early differentiation stage. This process could delay or restrain the completion of differentiation and, eventually, contribute to oncogenesis. Collectively, these results provide evidence that precise JAZF1 regulation during adipocyte differentiation from the early to the terminal stage might be necessary for the process to occur.
We focused on the transcriptional regulatory aspect during the adipocyte differentiation process to elucidate the JAZF1 mechanisms during adipose development and differentiation. JAZF1 was identified as a transcription regulator and functions as a repressor of transcription of NR2C2 . A study indicated that the enriched cytosolic JAZF1 that dynamically localized in nuclear upon stimulation with metabolic stress  may regulate the transcription activity of target nuclear receptors. In this context, a study demonstrated that JAZF1 is a positive transcriptional regulator of visfatin and promotes adipocyte differentiation and maturation . Moreover, JAZF1 directly affects the transcription of ribosome biogenesis and RNA processing-related genes in β-cell . Our findings expanded another JAZF1 mechanism that regulates the transactivation activity of PPARγ and adipogenic gene expressions, which are also responsible for maintaining adipocyte differentiation. To sum up, we suggesting that JAZF1 acts as a positive regulator of adipocyte differentiation through PPARγ.
However, how JAZF1 functionally interacts with PPARγ is currently unknown. One possible explanation is that JAZF1 affects adipocyte differentiation and PPARγ activity through AKT regulation—a coactivator of PPARs [26,27,28]. We found that JAZF1 deficiency led to decreased AKT activity in the eWAT and liver, in response to excessive insulin stimulation. This result is consistent with the finding that mice overexpressing JAZF1 show increased phosphoinositide-3-kinase/AKT activation in both the adipose tissue and liver .
The relationship between glucose homeostasis and JAZF1 was previously reported in the JAZF1 overexpression model. JAZF1 overexpression in transgenic mice improved insulin sensitivity and protected HFD-induced obesity [13, 21, 30]. In this study, JAZF1-deficient mice showed impaired glucose homeostasis. However, although JAZF1-deficient mice showed adiposity reduction, their insulin resistance was more developed than control mice. These observations are similar to those found previously in lipodystrophy models, in which, the resistance to lipid accumulation in dysfunctional adipose tissue causes insulin resistance with dyslipidemia [31, 32]. Compared to the control mice, the JAZF1-deficient mice had less adipose tissue mass and showed insulin resistance, with a perturbed lipid profile. However, we did not observe the development of ectopic fat accumulation, particularly in the liver of mice fed with an ND, as observed in the lipodystrophy models. One possibility is that reduced JAZF1 expression in our whole-body JAZF1-deficient mice might have inhibited fat accumulation in the liver, supported by the lower expression trend in lipogenesis-related genes in their liver. On the other hand, the inability and dysfunctional adipose tissue cause decreased secretion of insulin-sensitizing adipokines, such as leptin and adiponectin, contributing to insulin resistance. We also found reduced leptin and adiponectin mRNA expressions in both the eWAT and scWAT tissues of JAZF1-deficient mice.
We also observed an increased infiltration of monocyte and macrophage in adipose tissue and liver in JAZF1-deficient mice. Increased macrophage and immune cell infiltration is often associated with inflammation and leads to insulin resistance . Indeed, JAZF1 can control the adipose tissue macrophage by regulating their antigen presentation function and populations [13, 14]. The dysregulated lipid metabolism and the change in glucose homeostasis in JAZF1-deficient mice are attributed to the role of JAZF1, in the development and differentiation of adipose tissues, which partially occurs through PPARγ. Remarkably, the inhibition of adipose development in JAZF1-deficient mice is manifested by the reduced PPARγ transcriptional activity and related genes in eWAT and scWAT, reducing lipid accumulation, maturation, and insulin-sensitizing adipokines expressions, such as leptin and adiponectin.
Our study on JAZF1-deficient mice showed that JAZF1 is involoved in metabolism, affecting fat accumulation and insulin sensitivity in metabolic-related tissues, but some limitations must be considered. Overall, the metabolic phenotypes were moderate in our heterogynous JAZF1-deficient mice. We found that fat accumulation in eWAT was inhibited in our JAZF1-deficient mice, which is correlated with the decrease in JAZF1 expression levels. However, scWAT and liver tissues showed lower metabolic changes with less decreased JAZF1 expression. Therefore, the moderate phenotypes we observed in these mice could be due to the JAZF1 downregulation efficiency. It would be better to address the JAZF1 function on adipose tissue development and metabolism by establishing a tissue-specific JAZF1 knockout mice model.
We demonstrated that role of JAZF1 in adipose tissue development and related metabolism. These results support a new insight into the critical JAZF1 function in systemic metabolism. Our findings may be helpful for the treatment of metabolic diseases, such as obesity and diabetes.
Generation of heterozygous JAZF1 deletion mice
The gene-targeting vector with the loxP site flanking the critical exon 2 of JAZF1 was constructed by EUCOMM (European Conditional Mouse Mutagenesis Program) consortium. Heterozygous mice carrying a JAZF1tm1a (EUCOMM)Wtsi allele were established from Macrogen (Seoul, Korea). The schematic procedure for generating the heterozygous JAZF1 deletion (JAZF1-Het) mice is shown in Additional file 1: Figure S2a. The offspring genotype was confirmed by PCR, using tail biopsies from homozygous JAZF1 deletion (JAZF1-KO), JAZF1-Het, and their littermate wild-type control (JAZF1-Cont) pups (Additional file 1: Figure S2b). Briefly, mice carrying the wild-type allele were confirmed using oligonucleotide primers 5ʹ-arm and 3ʹ-arm, which produced a 426-bp product. The presence of the targeted allele was confirmed using oligonucleotide primers 5ʹ-arm and LAR3, which produced a 321-bp product. Mice carrying the mutated allele produced by Cytomegalovirus (CMV)-Cre-recombination were confirmed using oligonucleotide primers Cre-forward and Cre-reverse, which produced a 641-bp product. All oligonucleotide sequences are provided in Additional file 1: Table S1.
Animal and diet treatment
All animal experiments adhered to the guidelines for animal experimentation of the Kyungpook National University Animal Care and Use Committee and were approved by the ethics committee. For the diet treatment, JAZF1-Het and JAZF1-Cont mice were divided into two groups and fed the ND (Feedlab, Guri-si, Korea) or the HFD, containing 60% fat on a caloric basis (Research Diets, New Brunswick, NJ) for 8 weeks. Mice were housed in a controlled environment with alternating 12-h light and dark cycles and free access to food and water. Bodyweight and food intake were measured every week during the entire experiment period. Unless otherwise indicated, all animal experiments were performed using male mice.
Paraffin sections (5-μm-thick) were deparaffinized with xylene and rehydrated with graded ethanol. Deparaffinized epididymal white adipose tissue (eWAT), subcutaneous white adipose tissue (scWAT), and liver sections were stained with hematoxylin and eosin (H&E), using standard histological techniques . For analysis of adipocyte diameters and nuclei numbers from eWAT and scWAT, 3–8 random microscopic field (20× objective) images were taken from each mouse using Olympus BX51 (Olympus, Tokyo, Japan). Immunohistochemistry (IHC) staining was performed to examine the macrophage and monocyte cell infiltration. Deparaffinized and rehydrated eWAT and liver paraffin sections were treated with a 10-mM citrate buffer (pH 6.0) for antigen retrieval. The primary antibody was incubated overnight at 4 °C (rabbit anti-CD68, 1:100; ThermoFisher). The staining was visualized using the EnVision™ Detection System (Dako, Glostrup, Denmark). For analysis of CD68 positive cells from eWAT and liver, five–eight random microscopic field (20× objective) images were taken from each mouse using Olympus BX51.
Body composition analysis
eWAT, scWAT, BAT, and liver were carefully dissected after the mice were sacrificed. The tissues were weighed and normalized to the whole body weight (BW) to quantify body mass. Additionally, total body fat and lean mass compositions were also assessed using a microcomputed tomography (CT) system (Quantum FX; PerkinElmer, Waltham, MA).
Indirect calorimetry analysis
The volume of oxygen consumption (VO2), carbon dioxide production (VCO2), RER, heat production, and energy expenditure were measured using an indirect calorimetry system (Oxymax; Columbus Instruments, Columbus, OH). Mice were adapted for 3 days in a metabolic cage before recording, and data was collected for 24 h.
Glucose tolerance test and insulin tolerance test
GTT and ITT were performed as described previously . Briefly, male and female mice were fasted overnight (16 h) before the GTT. After fasting, the mice were intraperitoneally injected (i.p.) with glucose (1.5 g/kg BW). Blood glucose level was determined by tail bleeds at 0, 15, 30, 60, and 120 min using the Accu-Chek ® glucometer (Roche Diagnostics, Basel, Switzerland). The ITT was done similarly to the GTT experiment, except that the mice fasted for only 8 h and insulin (2 U/Kg bodyweight) was administered by ip injection.
Measurement of serum insulin levels
According to the manufacturer’s instructions, the serum insulin levels were measured using a commercial mouse insulin Enzyme-Linked Immunosorbent Assay (ELISA) kit (ALPCO Diagnostic, Salem, NH).
Insulin signaling experiment
The mice were fasted for 15 h to investigate the insulin signaling and were then intraperitoneally injected with bovine insulin (2 U/Kg) or phosphate-buffered saline (PBS). Ten minutes later, eWAT, and liver were isolated and homogenized using a homogenizer (IKA, Japan). The tissue lysates were stored at − 80 °C until the further experiment.
Blood biochemical analysis
Blood samples were obtained by retroorbital bleeding. Samples were collected in blood collection tubes and were allowed to clot at room temperature for 2 h. Each clotted blood sample was centrifuged at 2000×g and 4 °C for 15 min and stored at − 80 °C until the further experiment. Biochemical analysis was performed using an automatic biochemical analyzer (PerkinElmer, Waltham, MA).
Adipocyte differentiation in vitro
The 3T3-L1 preadipocytes were maintained in DMEM (Gibco, Waltham, MA) containing 10% calf serum (Gibco, Waltham, MA). The 3T3-L1 preadipocytes were cultured in DMEM containing 10% fetal bovine serum (FBS; Gibco, Waltham, MA) until they reached confluence to induce adipogenic differentiation. At confluence, the cells were treated with MDI (methylisobutylxanthine, dexamethasone, insulin) induction medium [DMEM containing 10% FBS, 1 μg/ml insulin, 10 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine (all from Sigma, St. Louis, MO)]. After 2 days, the cells were maintained in an insulin medium (DMEM containing 10% FBS and 1 μg/ml insulin) for 6 days. The medium was replaced every 2 days.
MEFs were isolated from E13.5d mice embryos under a dissecting microscope. MEFs were maintained in DMEM containing 10% FBS and a nonessential amino acid solution (Gibco). For inducing adipogenic differentiation, MEFs were cultured in DMEM containing 10% FBS, until they reached confluence. At confluence, the cells were treated with the DMI induction medium [MEM-α (Gibco) containing 10% FBS, 5 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine] supplemented with 5 μM rosiglitazone (Sigma). After 2 days, the cells were cultured in an insulin medium (MEM-α containing 10% FBS and 5 μg/ml insulin) supplemented with 5 μM rosiglitazone for 8–10 days. The medium was replaced every 2 days.
Adipose tissue fractionation
eWAT from wild-type C57BL/6 mice was digested using collagenase. Adipocytes and SVFs were fractionated by centrifugation as previously described .
Oil red O staining
Lipid accumulation in differentiated adipocytes from MEFs was determined by the Oil red O staining method . The Oil red O staining was quantified using a spectrophotometer (PerkinElmer, Waltham, MA) at 550 nm wavelength, with 650 nm wavelength as a reference.
Total RNA was isolated from cells and tissues, as described previously . Reverse transcription was performed using PrimeScript™ 1st Strand cDNA Synthesis Kit (TaKaRa Bio, Kusatsu, Japan) following the manufacturer's instruction. Quantitative real-time PCR (qRT-PCR) was performed using SYBR Green I (TaKaRa Bio) and analyzed on a StepOnePlus™ Real-Time PCR System (Applied Biosystem, Foster City, CA). The oligonucleotide primer sets for qPCR are given in Additional file 1: Table S2. All data sets of relative mRNA expression levels were calculated based on the 2−∆∆CT method and normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Total proteins were extracted from cells and tissues using the Pro-Prep lysis buffer (iNtRON Biotechnology, Seoul, Korea), as described previously . Western blotting was performed using antibodies to JAZF1(Abcam), PPARγ (Santa Cruz), C/EBPβ (Santa Cruz), phospho-AKT (p-AKT; Cell signaling, Beverly, MA), total-AKT (t-AKT; Cell signaling), FABP4 (Santa Cruz), and β-Actin (Santa Cruz) as primary antibodies. Immunoblots were visualized using an ECL detection kit (GE Healthcare, Piscataway, NJ).
All data were expressed as the mean ± standard error of the mean (SEM). Statistically significant differences among the different experimental groups were determined using Student's t-test, with p < 0.05 being considered statistically significant.
Availability of data and materials
All data in this study are available upon request.
Area under the curve
Brown adipose tissue
Body mass index
CCAAT-enhancer-binding protein α
Epididymal white adipose tissue
Glucose tolerance test
Insulin tolerance test
Juxtaposed with another zinc finger protein 1
Mitotic clonal expansion
Mouse embryonic fibroblasts
Nonesterified fatty acids
Peroxisome proliferator-activated receptor γ
Respiratory exchange ratio
Subcutaneous adipose tissue
Subcutaneous white adipose tissue
Stromal vascular fractions
Type 2 diabetes mellitus
Visceral adipose tissue
- VCO2 :
Volume of carbon dioxide production
- VO2 :
Volume of oxygen consumption
Grarup N, Andersen G, Krarup NT, Albrechtsen A, Schmitz O, Jorgensen T, et al. Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes. 2008;57:2534–40.
Alharbi KK, Khan IA, Syed R, Alharbi FK, Mohammed AK, Vinodson B, et al. Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population. Diabetol Metab Syndr. 2015;7:92.
Ming GF, Li X, Yin JY, Ai YH, Xu DM, Ma XH, et al. JAZF1 regulates visfatin expression in adipocytes via PPARalpha and PPARβ/δ signaling. Metabolism. 2014;63:1012–21.
Lee YH, Nair S, Rousseau E, Allison DB, Page GP, Tataranni PA, et al. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia. 2005;48:1776–83.
Aguilera CM, Gomez-Llorente C, Tofe I, Gil-Campos M, Cañete R, Gil Á. Genome-wide expression in visceral adipose tissue from obese prepubertal children. Int J Mol Sci. 2015;16:7723–37.
Mathur SK, Jain P, Mathur P, Punjabi P, Agarwal A, Sharma A. Transcriptomic analysis of visceral adipose from healthy and diabetic obese subjects. Indian J Endocrinol Metab. 2013;17:446–50.
Nakajima T, Fujino S, Nakanishi G, Kim YS, Jetten AM. TIP27: a novel repressor of the nuclear orphan receptor TAK1/TR4. Nucleic Acids Res. 2004;32(14):4194–204.
Kang HS, Okamoto K, Kim YS, Takeda Y, Bortner CD, Dang H, et al. Nuclear orphan receptor TAK1/TR4-deficient mice are protected against obesity-linked inflammation, hepatic steatosis, and insulin resistance. Diabetes. 2011;60:177–88.
Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4:263–73.
Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135:798–800.
Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007;17:318–24.
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127:1–4.
Meng F, Lin Y, Yang M, Li M, Yang G, Hao P, et al. JAZF1 inhibits adipose tissue macrophages and adipose tissue inflammation in diet-induced diabetic mice. Biomed Res Int. 2018;2018:4507659.
Meng F, Hao P, Du H, Zhou Z. Effects of adenovirus-mediated overexpression of JAZF1 on chronic inflammation: an in vitro and in vivo study. Med Sci Monit Basic Res. 2020;26:e924124.
Langberg KA, Ma L, Sharma NK, Hanis CL, Elbein SC, Hasstedt SJ, et al. Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. J Hum Genet. 2012;57:57–61.
Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab. 2012;16:122–34.
Replication DIG, Meta-analysis C, Asian Genetic Epidemiology Network Type 2 Diabetes C, South Asian Type 2 Diabetes C, Mexican American Type 2 Diabetes C, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44.
Li JW, Lee HM, Wang Y, Tong AHY, Yip KY, Tsui SKW, et al. Interactome-transcriptome analysis discovers signatures complementary to GWAS Loci of Type 2 Diabetes. Sci Rep. 2016;6:35228.
Ming GF, Xiao D, Gong WJ, Liu HX, Liu J, Zhou HH, et al. JAZF1 can regulate the expression of lipid metabolic genes and inhibit lipid accumulation in adipocytes. Biochem Biophys Res Commun. 2014;445:673–80.
Li L, Yang Y, Yang G, Lu C, Yang M, Liu H, et al. The role of JAZF1 on lipid metabolism and related genes in vitro. Metabolism. 2011;60:523–30.
Wei Q, Zhou B, Yang G, Hu W, Zhang L, Liu R, et al. JAZF1 ameliorates age and diet-associated hepatic steatosis through SREBP-1c -dependent mechanism. Cell Death Dis. 2018;9:859.
Tang QQ, Otto TC, Lane MD. Mitotic clonal expansion: a synchronous process required for adipogenesis. Proc Natl Acad Sci U S A. 2003;100:44–9.
Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A. 2001;98:6348–53.
Sung Y, Park S, Park SJ, Jeong J, Choi M, Lee J, et al. Jazf1 promotes prostate cancer progression by activating JNK/Slug. Oncotarget. 2018;9:755–65.
Kobiita A, Godbersen S, Araldi E, Ghoshdastider U, Schmid MW, Spinas G, et al. The diabetes gene JAZF1 is essential for the homeostatic control of ribosome biogenesis and function in metabolic stress. Cell Rep. 2020;32:107846.
Humphrey SJ, Yang G, Yang P, Fazakerley DJ, Stöckli J, Yang JY, et al. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metab. 2013;17:1009–20.
Kim SP, Ha JM, Yun SJ, Kim EK, Chung SW, Hong KW, et al. Transcriptional activation of peroxisome proliferator-activated receptor-gamma requires activation of both protein kinase A and Akt during adipocyte differentiation. Biochem Biophys Res Commun. 2010;399:55–9.
Choi SM, Tucker DF, Gross DN, Easton RM, DiPilato LM, Dean AS, et al. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol. 2010;30:5009–20.
Yuan L, Luo X, Zeng M, Zhang Y, Yang M, Zhang L, et al. Transcription factor TIP27 regulates glucose homeostasis and insulin sensitivity in a PI3-kinase/Akt-dependent manner in mice. Int J Obes (Lond). 2015;39:949–58.
Jang WY, Bae KB, Kim SH, Yu DH, Kim HJ, Ji YR, et al. Overexpression of Jazf1 reduces body weight gain and regulates lipid metabolism in high fat diet. Biochem Biophys Res Commun. 2014;444:296–301.
Agarwal AK, Garg A. Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet. 2006;7:175–99.
Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33:305–31.
Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;2008:pdb.prot4986.
Jeong JI, Kim J, Kim KM, Choi I, Pratley RE, Lee Y-H. Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice. Anim Cells Syst. 2014;18:219–27.
Li L, Xie X, Qin J, Jeha GS, Saha PK, Yan J, et al. The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. Cell Metab. 2009;9:77–87.
Ramírez-Zacarías JL, Castro-Muñozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil Red O. Histochemistry. 1992;97:493–7.
Jang WY, Jeong J, Kim S, Kang MC, Sung YH, Choi M, et al. Serum amyloid A1 levels and amyloid deposition following a high-fat diet challenge in transgenic mice overexpressing hepatic serum amyloid A1. Appl Physiol Nutr Metab. 2016;41:640–8.
This work was supported by the BK-21 FOUR program through National Research Foundation of Korea (NRF) under Ministry of Education.
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1A4A1018280 and 2020R1I1A2075315). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (NRF-2021R1F1A1045382).
Ethics approval and consent to participate
All animal experiments adhered to the guidelines for animal experimentation of the Kyungpook National University Animal Care and Use Committee and were approved by the committee.
Consent for publication
The authors declare they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Human JAZF1 mRNA expression in adipose tissue on three GEO datasets (GSE2508, GSE9624, and GSE16415). Figure S2. Generation of heterozygous JAZF1 deletion mice. Figure S3. Histological and molecular analysis of liver in JAZF1-Het and JAZF1-Cont mice. Figure S4. Serum analysis in JAZF1-Het and JAZF1-Cont mice. Figure S5. Insulin signaling and glucose homeostasis-related gene analysis in various tissues of JAZF1-Het mice. Figure S6. Histological and molecular analysis in the liver of JAZF1-Het-HFD and JAZF1-Cont-HFD mice. Figure S7. Serum analysis in JAZF1-Het-HFD and JAZF1-Cont-HFD mice. Figure S8. Insulin signaling and glucose homeostasis-related gene analysis in various tissues of JAZF1-Het-HFD and JAZF1-Cont-HFD mice. Table S1. Mouse primer sequence for allele-specific genotyping. Table S2. Mouse primer sequences for qRT-PCR.
About this article
Cite this article
Jeong, J., Jang, S., Park, S. et al. JAZF1 heterozygous knockout mice show altered adipose development and metabolism. Cell Biosci 11, 161 (2021). https://doi.org/10.1186/s13578-021-00625-1